UK Markets closed
  • NIKKEI 225

    23,474.27
    -92.73 (-0.39%)
     
  • HANG SENG

    24,786.13
    +31.71 (+0.13%)
     
  • CRUDE OIL

    40.66
    +0.63 (+1.57%)
     
  • GOLD FUTURES

    1,905.00
    -24.50 (-1.27%)
     
  • DOW

    28,375.37
    +164.55 (+0.58%)
     
  • BTC-GBP

    10,032.14
    +1,610.55 (+19.12%)
     
  • CMC Crypto 200

    264.41
    +8.31 (+3.24%)
     
  • Nasdaq

    11,516.12
    +31.42 (+0.27%)
     
  • ^FTAS

    3,268.54
    +7.53 (+0.23%)
     

Global Pharma, Biotech and Diagnostics Asset Purchase Partnering Deals Analysis 2014-2020

Research and Markets
·6-min read

Dublin, Oct. 13, 2020 (GLOBE NEWSWIRE) -- The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.

Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations

Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit

Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product

Technology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation

This report contains a comprehensive listing of over 1,000 asset purchase deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in Asset Purchase dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about Asset Purchase alliances.

Key benefits

  • In-depth understanding of asset purchase deal trends since 2014

  • Analysis of the structure of asset purchase agreements with numerous real life case studies

  • Comprehensive access to over 1,000 actual asset purchase deals entered into by the world's biopharma companies

  • Detailed access to actual asset purchase deals entered into by leading biopharma companies

  • Insight into the terms included in a asset purchase agreement, together with real world clause examples

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Therapeutic area

  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Asset Purchase dealmaking
2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in Asset Purchase deals since 2014
2.3.1. Asset Purchase dealmaking by year since 2014
2.3.2. Asset Purchase dealmaking by phase of development since 2014
2.3.3. Asset Purchase dealmaking by industry sector since 2014
2.3.4. Asset Purchase dealmaking by therapy area since 2014
2.3.5. Asset Purchase dealmaking by technology type since 2014
2.3.6. Asset Purchase dealmaking by most active company since 2014
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.3. The future of royalty asset purchase deals
2.6. The role of IP auction houses in asset purchase deals
2.6.1. Leading IP auction companies
2.7. The future of asset purchase agreements

Chapter 3 - Overview of Asset Purchase deal structure
3.1. Introduction
3.2. Asset purchase agreement structure
3.3. Example asset purchase agreements
3.3.1. Case study 1: Product asset: QLT - Valeant Pharmaceuticals
3.3.2. Case study 2: Business asset: Merck and Co - Bayer
3.4. Anatomy of a royalty asset purchase agreement
3.5. Example royalty asset purchase agreements
3.5.1. Case study 3: Royalty asset: BioTime Acquisition Corporation - Geron Corporation

Chapter 4 - Leading Asset Purchase deals
4.1. Introduction
4.2. Top Asset Purchase deals by value

Chapter 5 - Top 25 most active Asset Purchase dealmakers
5.1. Introduction
5.2. Top 25 most active Asset Purchase dealmakers

Chapter 6 - Asset Purchase deals including contracts directory
6.1. Introduction
6.2. Asset Purchase deals with contracts since 2014

Appendices
Appendix 1 - Asset Purchase dealmaking by companies A-Z
Appendix 2 - Asset Purchase dealmaking by industry sector
Appendix 3 - Asset Purchase dealmaking by stage of development
Appendix 4 - Asset Purchase dealmaking by therapy area
Appendix 5 - Asset Purchase dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/dv5bgg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900